Dendritic cells vaccines

Elamanchili P, Diwan M, Cao M et al (2004) Characterization of poly(D, L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22 2406—2412... 

Copland MJ, Baird MA, Rades T et al (2003) Liposomal delivery of antigen to human dendritic cells. Vaccine 21 883-890... 

Waeckerle-Men Y, Allmen EU, Gander B et al (2006) Encapsulation of proteins and peptides into biodegradable poly(D, L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 24 1847-1857... 

Bungener L et al (2002) Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20 2287-2295... 

Key words Liposomes, Mannan, Dendritic cells, Vaccines, Mannosylated liposomes... 

Morisaki, T., K. Matsumoto, H. Onishi, H. Kuroki, E. Baba, A. Tasaki, M. Kubo, M. Nakamura, S. Inaba, K. Yamaguchi, M. Tanaka, and M. Katano (2003) Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients rationale, current progress, and perspectives. Hum Cell 16 175-182. 

Wu, Q., Xia, D., Carlsen, S., and Xiang, J. 2005. Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer. Curr. Gene Ther. 5, 237-247. 

Xiao BG, Huang YM, Link H. Dendritic cell vaccine design strategies for eliciting peripheral tolerance as therapy of autoimmune diseases. BioDrugs 2003 17 103-111. 

Schott M, Feldkamp J, Klucken M, Kobbe G, Scherbaum WA, Seissler J. Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol Immunother 2002 51 663—668. 

Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Taikesako K, Akiyoshi T, Mori M. Dendritic cell vaccination with mage peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001 7 2277-2284. 

Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004 53 275-306. 

Trakatelli M et al. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother 2006 55 469-474. 

Fadul C. DMS-0536 A Phase II Feasibility Study of Adjuvant Intra-Nodal Autologous Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme, 2006. 

Krishnadas DK, Shapiro T, Lucas K. Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma. Pediatrics. 2013 1312 e336 1. 

Wolf B, Schwarzer A, Cote AL, Hampton TH, Schwaab T, Huarte E, Tomlinson CR, Gui J, Fisher JL, Fadul CE, Hamilton JW, Emstoff MS. Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-a and dendritic cell vaccine. PLoS One. 2012 7(12) e50221. 

As stated earlier, dendritic cells and macrophages are valuable antigen-presenting cells (APCs). These cells express MBPs and, as such, they constitute important entry mechanisms for vaccine targeting. Thus, instead of linking short peptide antigens to... 

Gamvrellis A, Leong D, Hanley JC et al (2004) Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol 82 506-516... 

Reddy ST, Swartz MA, Hubbell JA (2006) Targeting dendritic cells with biomaterials developing the next generation of vaccines. Trends Immunol 27 573-579... 

Jilek S, Merkle HP, Walter E (2005) DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev 57 377-390... 

Sun H, Pollock KG, Brewer JM (2003) Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21 849-855... 

Hamasaki T, Uto TA et al (2010) Modulation of gene expression related to Toll-like receptor signaling in dendritic cells by poly(y-glutamic acid) nanoparticles. Clin Vaccine Immunol 17 748-756... 

The activation of a T-cell response and subsequent efficacy of DNA vaccines is ultimately determined by professional antigen presenting cells, such as macrophages, dendritic cells, and Langerhans cells (Corr et al., 1996 Doe et al., 1996 Iwasaki et al., 1997 Ulmer et al., 1996). It follows that successful DNA vaccination strategies should seek to target DNA... 

Ou-Yang, P. et al., Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine Role of dendritic cells, J. Med. Virol., 66, 320, 2002. 

Provenge is a cancer vaccine using cell therapy technique. Dendritic cells are removed from patients. These cells are treated with the prostate-specific antigen prostatic acid phosphatase (PAP), which is present in 95% of prostate cancer cases. The activated dendritic cells are returned to the patients and they stimulate the T cells to destroy cancer cells expressing the PAP, thus treating the tumor. 

While the FDA is adopting a cautious approach to cancer vaccine, such as DCVax-Brain, the Swiss Institute of Public Health has conditionally allowed the use of this vaccine by patients. DCVax consists of a patient s dendritic cells that have been pulsed with antigens derived from a tumor cell lysate prepared from surgically resected glioblastoma (brain cancer) tissue. It was developed by a company in the United States but has not yet been approved by the FDA. 

Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ Tumor-derived TGF-(5 reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 2003 170 3806-3811. 

To review, in an experimental mouse model, LPDI/E7 vaccination both prevents the establishment of metastatic E7-expressing tumors in naive mice through an induced E7-specific T-cell immune response and, in mice with previously established E7-expressing tumors, causes tumor regression with one subcutaneous injection of LPDI/E7 [Han SJ, et al. Subcutaneous antigen loading of dendritic cells by liposome-protamine-DNA (LPD) nanoparticles results in their activation and induction of specific antitumor immune response (impublished)]. A robust immune response follows administration of LPDI/ peptide particles, which can be used as either a preventative or therapeutic cancer vaccination strategy due to the ability of the particles to prevent and eliminate tumors, respectively, in mouse models. 

Recent advances in understanding how immune responses are generated allows a particularly interesting approach using cytokines, co-stimulatory molecules, and professional antigen-presenting cells (e.g., dendritic cells) to enhance or otherwise modify vaccine responses [43 5], It is hkely that one or more of these adjuvant and delivery systems will be incorporated in the design of future vaccines. 

Steinman, R.M., and M. Pope, Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest, 2002.109(12) 1519-26. 

---